Is LeMaitre Vascular (LMAT) overvalued or fairly valued?

MarketChacha shows LeMaitre Vascular's valuation in context — a trailing P/E of about 30.0, a forward P/E of about 26.2, a price-to-book of about 4.5 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does LeMaitre Vascular's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.23×) from reported figures — education, not a rating.

What is LeMaitre Vascular's revenue?

LeMaitre Vascular reported revenue of $249.6M for FY2025, with net profit of $57.7M, per official filings.

What is the share price of LeMaitre Vascular (LMAT)?

LeMaitre Vascular last traded at $83.20 (+1.1% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

LeMaitre Vascular

LMAT · NYSE · Healthcare · United States

Snapshot

TickerLMAT

ExchangeNYSE

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryUnited States

Employees646

HeadquartersBurlington, United States

Websitewww.lemaitre.com

Filings tracked13

About LeMaitre Vascular

LeMaitre Vascular, Inc. develops, manufactures, and markets medical devices and implants used in the field of vascular surgery in the Americas, Europe, the Middle Esat, Africa, and the Asia Pacific. The company offers allografts, which are cryopreserved human tissue grafts used in vascular reconstruction, and cardiac repair and reconstruction; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature, as well as human cadaver tissue cryopreservation services. It provides a suite of biologic products comprising artegraft biologic graft, a bovine carotid artery used for dialysis access; XenoSure biologic patches used for vessel closure after surgical intervention; VascuCel and CardioCel biologic patches, used in vessel repair, heart repair and reconstruction, and neonatal repairs; carotid shunts that temporarily shunt the blood to the brain; biosynthetic vascular grafts indicated for lower extremity bypass and dialysis access; phlebectomy system for resection and ablation of varicose veins; LifeSpan vascular grafts, which are expanded polytetrafluoroethylene grafts; and vascular grafts used to bypass or replace diseased arteries. In addition, the company offers radiopaque tape, a medical-grade tape; valvulotomes, which cut or disrupt valves in the saphenous vein to function as an artery to carry blood past diseased arteries to the lower leg or the foot; and closure systems to attach vessels to one another with titanium clips instead of sutures. It markets its products through a direct sales force and distributors. The company was formerly known as Vascutech, Inc. and changed its name to LeMaitre Vascular, Inc. in April 2001. LeMaitre Vascular, Inc. was incorporated in 1983 and is headquartered in Burlington, Massachusetts.

Who owns it

Insiders6.5%
Institutions93.5%
Public & other0.0%

439 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.14.31%
Conestoga Capital Advisors, LLC5.98%
First Trust Advisors LP4.78%
Congress Asset Management Co4.20%
Vanguard Capital Management LLC4.17%
Copeland Capital Management, LLC4.04%
State Street Corporation3.94%
Geode Capital Management, LLC3.45%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.23×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend15.6% → 23.1%

Margin has expanded by about 7.6 points — the business is getting more profitable.

Growth qualityrev 14% · PAT 38%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $72.2M · EPS 0.78

Est. earnings growth +14.3%

Next fiscal year

Rev $302.9M · EPS 3.18

Est. earnings growth +10.4%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$249.6M

Net margin

23.1%

ROE

14.7%

Revenue CAGR (2y)

+13.6%

Profit CAGR (2y)

+38.5%

EPS (FY2025)

2.52

Net profit (FY2025)

$57.7M

Ask MarketChacha about LMAT

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$249.6M	$57.7M	2.52	23.1%	14.7%
FY2024	$219.9M	$44.0M	1.93	20.0%	13.1%
FY2023	$193.5M	$30.1M	1.34	15.6%	10.1%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$70.4M	$17.1M	0.74	24.2%
2026Q1	$66.6M	$15.7M	0.68	23.6%
2025Q3	$61.0M	$17.4M	0.75	28.4%
2025Q2	$64.2M	$13.8M	0.60	21.5%
2025Q1	$59.9M	$11.0M	0.48	18.4%
2024Q3	$54.8M	$11.1M	0.49	20.3%
2024Q2	$55.8M	$11.8M	0.52	21.2%
2024Q1	$53.5M	$9.9M	0.44	18.5%
2023Q4	$48.9M	$8.5M	0.38	17.3%
2023Q3	$47.4M	$7.5M	0.33	15.8%
2023Q2	$50.1M	$8.1M	0.36	16.2%
2023Q1	$47.1M	$6.0M	0.27	12.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/5/2026
8-K — Results of operations, Exhibits
SEC8/4/2026material
8-K — Shareholder vote results
SEC6/5/2026material
10-Q filing
SEC5/6/2026
8-K — Results of operations, Exhibits
SEC5/5/2026material
8-K — Executive/director change, Other events
SEC4/14/2026material
10-K filing
SEC2/26/2026
8-K — Results of operations, Exhibits
SEC2/25/2026material

2025

8-K/A — Shareholder vote results
SEC11/7/2025
10-Q filing
SEC11/7/2025
8-K — Results of operations, Exhibits
SEC11/6/2025material
10-Q — FORM 10-Q
SEC8/6/2025
8-K — Results of operations, Exhibits
SEC8/5/2025material

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.